Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
28
ELDN Quote, Financials, Valuation and Earnings
Last price:
$1.58
Seasonality move
:
-1.34%
Day range:
$1.52 - $1.61
52-week range:
$1.35 - $4.98
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.33x
Volume:
353.5K
Avg. volume:
1.8M
1-year change:
-63.23%
Market cap:
$117.8M
Revenue:
--
EPS (TTM):
-$1.20
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ELDN
Eledon Pharmaceuticals, Inc.
|
-- | -$0.25 | -- | -72.97% | $8.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ELDN
Eledon Pharmaceuticals, Inc.
|
$1.57 | $8.00 | $117.8M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ELDN
Eledon Pharmaceuticals, Inc.
|
0.79% | 2.368 | 0.34% | 6.53x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ELDN
Eledon Pharmaceuticals, Inc.
|
-- | -$19.1M | -78.27% | -78.86% | -- | -$14.5M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Eledon Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ELDN or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Eledon Pharmaceuticals, Inc.'s net margin of -255.85%. Eledon Pharmaceuticals, Inc.'s return on equity of -78.86% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ELDNEledon Pharmaceuticals, Inc.-- -$0.23 $91.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ELDN or NBY?
Eledon Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 409.55%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Eledon Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Eledon Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELDNEledon Pharmaceuticals, Inc.7 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ELDN or NBY More Risky?
Eledon Pharmaceuticals, Inc. has a beta of 0.793, which suggesting that the stock is 20.652% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ELDN or NBY?
Eledon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Eledon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELDN or NBY?
Eledon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Eledon Pharmaceuticals, Inc.'s net income of -$17.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Eledon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eledon Pharmaceuticals, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELDNEledon Pharmaceuticals, Inc.-- -- -- -$17.5M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns ELDN or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Eledon Pharmaceuticals, Inc.'s net margin of --. Eledon Pharmaceuticals, Inc.'s return on equity of -78.86% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital ELDNEledon Pharmaceuticals, Inc.-- -$0.23 $91.8M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About ELDN or NNVC?
Eledon Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 409.55%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that NanoViricides, Inc. has higher upside potential than Eledon Pharmaceuticals, Inc., analysts believe NanoViricides, Inc. is more attractive than Eledon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELDNEledon Pharmaceuticals, Inc.7 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is ELDN or NNVC More Risky?
Eledon Pharmaceuticals, Inc. has a beta of 0.793, which suggesting that the stock is 20.652% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock ELDN or NNVC?
Eledon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eledon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELDN or NNVC?
Eledon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Eledon Pharmaceuticals, Inc.'s net income of -$17.5M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Eledon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eledon Pharmaceuticals, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELDNEledon Pharmaceuticals, Inc.-- -- -- -$17.5M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns ELDN or OGEN?
Oragenics, Inc. has a net margin of -- compared to Eledon Pharmaceuticals, Inc.'s net margin of --. Eledon Pharmaceuticals, Inc.'s return on equity of -78.86% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ELDNEledon Pharmaceuticals, Inc.-- -$0.23 $91.8M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ELDN or OGEN?
Eledon Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 409.55%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Eledon Pharmaceuticals, Inc. has higher upside potential than Oragenics, Inc., analysts believe Eledon Pharmaceuticals, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELDNEledon Pharmaceuticals, Inc.7 0 0 OGENOragenics, Inc.1 0 0 -
Is ELDN or OGEN More Risky?
Eledon Pharmaceuticals, Inc. has a beta of 0.793, which suggesting that the stock is 20.652% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock ELDN or OGEN?
Eledon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eledon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELDN or OGEN?
Eledon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Eledon Pharmaceuticals, Inc.'s net income of -$17.5M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Eledon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eledon Pharmaceuticals, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELDNEledon Pharmaceuticals, Inc.-- -- -- -$17.5M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ELDN or PTN?
Palatin Technologies has a net margin of -- compared to Eledon Pharmaceuticals, Inc.'s net margin of --. Eledon Pharmaceuticals, Inc.'s return on equity of -78.86% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ELDNEledon Pharmaceuticals, Inc.-- -$0.23 $91.8M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ELDN or PTN?
Eledon Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 409.55%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Eledon Pharmaceuticals, Inc., analysts believe Palatin Technologies is more attractive than Eledon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELDNEledon Pharmaceuticals, Inc.7 0 0 PTNPalatin Technologies0 0 0 -
Is ELDN or PTN More Risky?
Eledon Pharmaceuticals, Inc. has a beta of 0.793, which suggesting that the stock is 20.652% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ELDN or PTN?
Eledon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eledon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELDN or PTN?
Eledon Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Eledon Pharmaceuticals, Inc.'s net income of -$17.5M is higher than Palatin Technologies's net income of --. Notably, Eledon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eledon Pharmaceuticals, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELDNEledon Pharmaceuticals, Inc.-- -- -- -$17.5M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ELDN or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Eledon Pharmaceuticals, Inc.'s net margin of --. Eledon Pharmaceuticals, Inc.'s return on equity of -78.86% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ELDNEledon Pharmaceuticals, Inc.-- -$0.23 $91.8M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ELDN or TOVX?
Eledon Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 409.55%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Eledon Pharmaceuticals, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Eledon Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ELDNEledon Pharmaceuticals, Inc.7 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ELDN or TOVX More Risky?
Eledon Pharmaceuticals, Inc. has a beta of 0.793, which suggesting that the stock is 20.652% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock ELDN or TOVX?
Eledon Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eledon Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ELDN or TOVX?
Eledon Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Eledon Pharmaceuticals, Inc.'s net income of -$17.5M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Eledon Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eledon Pharmaceuticals, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ELDNEledon Pharmaceuticals, Inc.-- -- -- -$17.5M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
